Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study - Scorecard - MDSpire

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

  • By

  • Wenfang Jin

  • Ying Zhao

  • Yanling Lv

  • Yu Yao

  • Xin Su

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Baseline CD4/CD8 Lymphocyte Ratio as a Predictor of Early Immune-Related Adverse Events in Lung Cancer Patients Undergoing Immune Checkpoint Inhibition: A Retrospective Analysis from a Single Center

At a Glance

CategoryDetail
Condition
Key MechanismsBaseline CD4/CD8 ratio as a predictor of immune-related adverse events (irAEs) - ensure this is directly supported.
Target Population
Care Setting

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

    Management

    • M
    • o
    • n
    • i
    • t
    • o
    • r
    • p
    • a
    • t
    • i
    • e
    • n
    • t
    • s
    • f
    • o
    • r
    • e
    • a
    • r
    • l
    • y
    • i
    • r
    • A
    • E
    • s
    • ,
    • p
    • a
    • r
    • t
    • i
    • c
    • u
    • l
    • a
    • r
    • l
    • y
    • t
    • h
    • o
    • s
    • e
    • w
    • i
    • t
    • h
    • a
    • C
    • D
    • 4
    • /
    • C
    • D
    • 8
    • r
    • a
    • t
    • i
    • o
    • <
    • 1
    • .
    • 6
    • 5
    • -
    • e
    • n
    • s
    • u
    • r
    • e
    • t
    • h
    • i
    • s
    • i
    • s
    • d
    • i
    • r
    • e
    • c
    • t
    • l
    • y
    • c
    • i
    • t
    • e
    • d
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Single-agent PD-1/PD-L1 inhibitors are viable for elderly or chemotherapy-ineligible patients - ensure this is directly supported.

        Clinical Best Practices

        • remove

        Related Resources & Content

        Original Source(s)

        Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

        • by Wenfang Jin, Ying Zhao, Yanling Lv, Yu Yao, Xin Su

        • June 8, 2026

        Related Content

        The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

        Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential

        Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes